Celyad Oncology S.A.
CYAD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $19 | $11 | $10 | $50 |
| - Cash | $0 | $7 | $12 | $30 |
| + Debt | $0 | $1 | $0 | $3 |
| Enterprise Value | $19 | $5 | -$2 | $23 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 82.4% | – | – | – |
| Gross Profit | $0 | $0 | -$1 | -$2 |
| % Margin | 93.5% | 32.4% | – | – |
| EBITDA | -$6 | -$8 | -$40 | -$25 |
| % Margin | -3,057.5% | -7,610.8% | – | – |
| Net Income | -$6 | -$8 | -$41 | -$27 |
| % Margin | -3,131.2% | -8,282.4% | – | – |
| EPS Diluted | -0.14 | -0.33 | -1.81 | -1.7 |
| % Growth | 57.6% | 81.8% | -6.5% | – |
| Operating Cash Flow | – | -$15 | -$28 | -$27 |
| Capital Expenditures | – | -$1 | -$0 | -$0 |
| Free Cash Flow | – | -$16 | -$28 | -$27 |